Avicanna Announces Earnings Call for Financial Insights

Avicanna to Host Earnings Conference Call for 2024

Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is excited to announce a conference call led by Aras Azadian, the Chief Executive Officer, alongside Phil Cardella, the Chief Financial Officer. During this call, they will delve into the financial results for the full year of 2024.

Details of the Call

The Company plans to file its financial results for the full year after the market closes. The earnings call is scheduled for 8:30 AM ET on the following day. Participants are invited to join this informative session, where insights into the Company’s performance and future directions will be shared.

About Avicanna

Avicanna is more than just a biopharmaceutical company; it is a pioneer in developing, manufacturing, and commercializing cannabinoid-based products and formulations aimed at addressing various medical needs. The Company boasts a robust scientific foundation supported by research and development, leading to more than thirty proprietary products available to consumers. Notably, Avicanna operates through four key business pillars that encompass the full spectrum of cannabinoid-based solutions.

1. Medical Cannabis Formulary (RHO Phyto™)

The RHO Phyto formulary offers an array of cannabinoid products designed for different delivery methods, such as oral, sublingual, topical, and transdermal. This diversification supports ongoing patient education initiatives across various healthcare settings. RHO Phyto is well-established within the Canadian market and is ambitiously expanding its footprint internationally.

2. Medical Cannabis Care Platform (MyMedi.ca)

The MyMedi.ca platform provides tailored support for medical cannabis patients, enriching their experience and ensuring their specific needs are met effectively. Managed by Northern Green Canada Inc., it includes a variety of products and bilingual pharmacist-led support. In addition, MyMedi.ca offers educational resources for healthcare professionals to integrate medical cannabis into patient regimens seamlessly.

3. Pharmaceutical Pipeline

Through its advanced scientific platform, Avicanna is developing a proprietary pipeline of cannabinoid-based candidates targeting significant medical conditions. These indications range from dermatological issues to chronic pain management and various neurological disorders, showcasing the Company’s commitment to addressing critical healthcare needs.

4. Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS (“SMGH”), plays a vital role in supplying high-quality cannabinoids. This integration ensures a steady supply of CBD, THC, and CBG for global partners in food, cosmetics, medical, and pharmaceutical sectors, ensuring that the quality of their products meets the highest standards.

Stay Connected with Avicanna

For further inquiries or information about Avicanna, interested individuals can visit our website or reach out via email to Ivana Maric at info@avicanna.com.

Frequently Asked Questions

What is the purpose of the earnings call?

The call aims to discuss Avicanna's financial results for the full year of 2024, sharing insights and future growth strategies.

Who will be leading the earnings call?

The earnings call will be led by Aras Azadian, the CEO, and Phil Cardella, the CFO of Avicanna.

What products does Avicanna offer?

Avicanna offers a variety of cannabinoid-based products for medical and commercial applications across several formats.

How can patients access Avicanna's products?

Patients can access Avicanna products through their established formulary, RHO Phyto™, and the MyMedi.ca platform that supports medical cannabis care.

Where is Avicanna based?

Avicanna is a Toronto-based company that operates on an international scale, catering to medical and pharmaceutical markets worldwide.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.